603127.SH
昭衍新药
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 46.39
−5.85%Year over year
Reported trailing growth
- Revenue
- -14.9%
- EBITDA
- —
- EBIT
- +21.9%
- EPS
- +30.0%
- Free cash flow
- +52.1%
- Operating cash flow
- +78.5%
Forward estimates
Based on analyst estimates
- Revenue
- -53.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -9.9%
- EBITDA
- -29.4%
- EBIT
- -34.9%
- Net income
- -34.8%
- EPS
- -34.8%
- Free cash flow
- -24.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026